Mountain View, CA – According to filings with the U.S. Securities and Exchange Commission, NeuroPace is raising $96,385,618.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Michael Favet played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NeuroPace

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company’s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. The RNS System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world’s first and only medical device that can monitor and respond to brain activity.

To learn more about NeuroPace, visit http://www.neuropace.com/

Contact:
Michael Favet, President and Chief Executive Officer
650-237-2700
https://www.linkedin.com/in/michael-favet-45bb993/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved